{
    "eid": "2-s2.0-85152516753",
    "title": "Real-world clinical practice and outcomes in treating stage III non-small cell lung cancer: KINDLE-Asia subset",
    "cover-date": "2023-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Cancer Research",
            "@code": "1306",
            "@abbrev": "BIOC"
        }
    ],
    "keywords": [
        "adenocarcinoma",
        "concurrent chemoradiotherapy (CCRT)",
        "EGFR mutation",
        "lung cancer",
        "stage III NSCLC",
        "targeted therapy"
    ],
    "authors": [
        "Kumar Prabhash",
        "Daniel Shao Weng Tan",
        "Ross A. Soo",
        "Piyada Sitthideatphaiboon",
        "Yuh Min Chen",
        "Pei Jye Voon",
        "Elisna Syahruddin",
        "Sojung Chu",
        "Reto Huggenberger",
        "Byoung Chul Cho"
    ],
    "citedby-count": 0,
    "ref-count": 44,
    "ref-list": [
        "Chinese Guidelines for diagnosis and treatment of primary lung cancer 2018 (English version)",
        "Interdisciplinary multimodality management of stage III nonsmall cell lung cancer",
        "Clinical profile of lung cancer in north India: A 10-year analysis of 1862 patients from a tertiary care center",
        "The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM",
        "The 8th lung cancer TNM classification and clinical staging system: review of the changes and clinical implications",
        "Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020",
        "Treatment of non-small cell lung cancer (NSCLC)",
        "Ten-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study)",
        "Treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): Real-world experience in Singapore from the KINDLE study",
        "Outcomes of patients with unresected stage III and stage IV non-small cell lung cancer: A single institution experience",
        "A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)",
        "Asian Thoracic oncology research group expert consensus statement on optimal management of stage III NSCLC",
        "Asian Ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status",
        "Chinese Multi-institutional registry (CMIR) for resected non-small cell lung cancer: survival analysis of 5,853 cases",
        "A Japanese lung cancer registry study: Prognosis of 13,010 resected lung cancers",
        "Real-world treatment patterns and clinical outcomes in patients with stage III NSCLC: Results of KINDLE, a multicountry observational study",
        "STROBE initiative. strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration",
        "Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up",
        "Systemic treatment patterns with advanced or recurrent non\u2013small cell lung cancer in Japan: A retrospective hospital administrative database study",
        "Real-world outcomes in patients with unresected stage III non-small cell lung cancer",
        "Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O optimise initiative",
        "Real-world treatment of stage III NSCLC: The role of trimodality treatment in the era of immunotherapy",
        "Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer",
        "Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410",
        "Understanding clinical practice and survival outcomes in patients with unresectable stage III non-small-cell lung cancer in a single centre in Quebec",
        "The effect of different treatment modalities on survival in elderly patients with locally advanced non-small cell lung cancer",
        "Effects of multidisciplinary team care on the survival of patients with different stages of non-small cell lung cancer: a national cohort study",
        "Survival outcomes among lung cancer patients treated using a multidisciplinary team approach",
        "Does presentation at multidisciplinary team meetings improve lung cancer survival? findings from a consecutive cohort study",
        "Impact of the lung oncology multidisciplinary team meetings on the management of patients with cancer",
        "Osimertinib in resected EGFR-mutated non\u2013Small-Cell lung cancer",
        "Durvalumab after chemoradiotherapy in stage III non\u2013Small-Cell lung cancer",
        "Radiotherapy combined with gefitinib for patients with locally advanced non-small cell lung cancer who are unfit for surgery or concurrent chemoradiotherapy: a phase II clinical trial",
        "Combination strategies using EGFR-TKi in NSCLC therapy: Learning from the gap between pre-clinical results and clinical outcomes",
        "Review of the current targeted therapies for non-small-cell lung cancer",
        "Molecular epidemiological prospective study of EGFR mutations from Asian patients (pts) with advanced lung adenocarcinoma (PIONEER)",
        "OA05.03 real-world global data on targeting epidermal growth factor receptor in stage III non-small cell lung cancer: The results of the KINDLE study",
        "Osimertinib maintenance after definitive chemoradiation in patients with unresectable EGFR mutation positive stage III non-small-cell lung cancer: LAURA trial in progress",
        "Liquid biopsy for advanced NSCLC: A consensus statement from the international association for the study of lung cancer",
        "Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC-an update from the PACIFIC trial",
        "Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial",
        "Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria"
    ],
    "affiliation": [
        {
            "affiliation-city": "Cambridge",
            "@id": "60004219",
            "affilname": "AstraZeneca",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60004219",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Seoul",
            "@id": "60115402",
            "affilname": "Yonsei Cancer Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60115402",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Kuching",
            "@id": "60090650",
            "affilname": "Hospital Umum Sarawak",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60090650",
            "affiliation-country": "Malaysia"
        },
        {
            "affiliation-city": "Taipei",
            "@id": "60069716",
            "affilname": "National Yang-Ming University Taiwan",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60069716",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Depok",
            "@id": "60069377",
            "affilname": "Universitas Indonesia",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60069377",
            "affiliation-country": "Indonesia"
        },
        {
            "affiliation-city": "Singapore City",
            "@id": "60031809",
            "affilname": "National Cancer Centre, Singapore",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031809",
            "affiliation-country": "Singapore"
        },
        {
            "affiliation-city": "Mumbai",
            "@id": "60018517",
            "affilname": "Tata Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60018517",
            "affiliation-country": "India"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Singapore City",
            "@id": "108122270",
            "affilname": "National University Cancer Institute",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/108122270",
            "affiliation-country": "Singapore"
        }
    ],
    "funding": [
        "NSCLC",
        "AstraZeneca"
    ]
}